Jens C. Eickhoff, Ph.D.
Affiliations: | 2002 | Iowa State University, Ames, IA, United States |
Area:
Statistics, Biostatistics BiologyGoogle:
"Jens Eickhoff"Parents
Sign in to add mentorYasuo Amemiya | grad student | 2002 | Iowa State | |
(Generalized linear latent variable modeling analysis for multi -group studies.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Valentinuzzi D, Vrankar M, Boc N, et al. (2020) [18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab. Radiology and Oncology. 54: 285-294 |
Uboha NV, Lubner SJ, LoConte NK, et al. (2020) Phase 1 dose escalation trial of TAS-102 (trifluridine/tipiracil) and temozolomide in the treatment of advanced neuroendocrine tumors. Investigational New Drugs |
Uboha NV, Eickhoff JC, Chandrasekharan C, et al. (2020) Phase II study of the combination of abemaciclib and pembrolizumab in locally advanced unresectable or metastatic gastroesophageal adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149. Journal of Clinical Oncology. 38: TPS461-TPS461 |
Uboha NV, Lubner SJ, LoConte NK, et al. (2020) Phase I dose-escalation trial of trifluridine/tipiracil (TAS-102) and temozolomide in the treatment of advanced neuroendocrine tumors. Journal of Clinical Oncology. 38: 615-615 |
Deming DA, Emmerich P, Turk AA, et al. (2020) Pembrolizumab (Pem) in combination with stereotactic body radiotherapy (SBRT) for resectable liver oligometastatic MSS/MMR proficient colorectal cancer (CRC). Journal of Clinical Oncology. 38: 4046-4046 |
Uboha NV, Maloney JD, McCarthy D, et al. (2019) Phase I/II trial of perioperative avelumab in combination with chemoradiation in the treatment of stage II/III resectable esophageal cancer. Journal of Clinical Oncology. 37: TPS181-TPS181 |
Turk AA, Lubner SJ, Uboha NV, et al. (2019) A phase Ib study of pembrolizumab (Pem) in combination with stereotactic body radiotherapy (SBRT) for resectable liver metastatic colorectal cancer (CRC). Journal of Clinical Oncology. 37: 680-680 |
Bassetti MF, Turk AA, Lubner SJ, et al. (2019) A phase Ib study of pembrolizumab (Pem) in combination with stereotactic body radiotherapy (SBRT) for resectable liver metastatic MSS colorectal cancer (CRC): A postoperative safety analysis. Journal of Clinical Oncology. 37: e15047-e15047 |
Liu G, Fong L, Antonarakis ES, et al. (2019) Randomized phase II trial of a DNA vaccine encoding prostatic acid phosphatase (pTVG-HP) versus GM-CSF adjuvant in patients with PSA-recurrent prostate cancer. Journal of Clinical Oncology. 37: 5037-5037 |
Uboha NV, Maloney JD, McCarthy D, et al. (2019) Safety of neoadjuvant chemoradiation (CRT) in combination with avelumab (A) in the treatment of resectable esophageal and gastroesophageal junction (E/GEJ) cancer. Journal of Clinical Oncology. 37: 4041-4041 |